Held at the Lisbon Congress Centre, Portugal, from March 25–26 (with pre-day CEO forums on March 24), the 12th edition of LSX World Congress Europe (LSX26) marked a pivotal inflection point for the European life sciences ecosystem. For the first time, LSX26 was co-located with BIO-Europe Spring as part of Life Science Spring Innovation Week, creating a concentrated four-day corridor that brought together biotech, medtech, and pharmatech C-suites, venture capitalists, pharma business development and licensing leaders, and digital health innovators in a single city. With over 250 expert speakers, more than 4,000 prearranged one-to-one partner meetings, and an expanded three-track agenda spanning biotech leaders, medtech leaders, and the newly launched pharmatech leaders track, LSX26 signaled a decisive evolution in how the European life sciences industry is orienting toward AI-driven drug development, capital-efficient clinical translation, and globalized partnering strategies.
The conference, which has been held in London for a decade, relocated to Lisbon for the first time, a strategic move reflecting Southern Europe’s rapid emergence as a credible hub for life sciences innovation, growing talent pools, and increasing private capital flows. The joint evening reception at the historic Convento do Beato—the largest reception either event has hosted—underscored the scale and ambition of this convergence.
For healthcare and life sciences leaders navigating tightening capital markets, accelerating AI adoption, and a looming patent cliff, LSX26 delivered not just networking density but strategic clarity. This event byte distills the pivotal themes, technology-forward discussions, and analyst-level implications that emerged across the congress.
The most significant structural development at LSX26 was the introduction of the pharmatech leaders track, a dedicated content stream designed to bridge pharma executives with digital health technology providers. This expansion reflects an industry-wide recognition that AI and digital technologies are no longer peripheral innovation bets but are becoming foundational to competitive positioning across drug discovery, clinical development, and commercialization.
Key sessions including “Revolutionizing Healthcare: AI’s Transformative Role in Drug Discovery, Clinical Operations, and Precision Medicine,” featuring Philippe Pinton (SVP, Head of Global Research & Medical at Ferring Pharmaceuticals), Arturo Urrios (Venture Partner at Ysios Capital), and Mike Klein (CEO, Genomenon), examined how AI, machine learning, and digital technologies are being deployed across pharmaceutical workflows—from literature analysis and digital twins to precision medicine and clinical operations. Complementing this, the “Prompting Change: How LLMs are Being Utilised by Pharma” session explored how large language models (LLMs) are reshaping drug discovery, regulatory workflows, and clinical protocol design, while Loucif Ouyahia (Global Head of Digital Healthcare, Jazz Pharmaceuticals) led a parallel discussion on “AI Integration Beyond the Technology,” stressing that successful AI implementation in pharma demands organizational and behavioral change well beyond the technology itself. The discussions underscored that pharma’s AI adoption is maturing from isolated proof-of-concept pilots toward integrated, scalable deployments that touch multiple functions simultaneously.
AI-Powered Biomarkers and Precision Medicine
The “New Frontiers in CNS” panel, featuring executives from Eli Lilly, EQT Life Sciences, FundaMental Pharma, and Aerska, highlighted a critical convergence: AI-powered imaging biomarkers and digital biomarkers are emerging as essential tools for patient stratification, early disease detection, and accelerating proof of efficacy in complex therapeutic areas such as neurology. Eli Lilly’s Jenny Laird noted that 2026 represents a more stable period for central nervous system (CNS) development, with growing emphasis on biomarkers feeding forward into better clinical decision-making. EQT Life Sciences’ Juliette Lee advocated for digital biomarkers as instruments for tracking disease progression, moving beyond traditional clinical scales that are often subjective and insensitive to meaningful change.
This trajectory aligns with broader industry signals: AI is not merely accelerating timelines but fundamentally reshaping how efficacy is measured and demonstrated to investors, regulators, and pharma partners alike.
Platform Technologies and the Company vs. Asset Debate
A panel on “Platform Technologies: Building a Company vs. a Single Asset” explored how AI-enabled discovery platforms, such as those leveraging computational chemistry, protein engineering, and machine learning-driven screening, are redefining biotech valuation frameworks. Exhibitors featured companies including Curve Therapeutics, Evox Therapeutics, and Avata Biosciences, each demonstrating how platform approaches generate multiple pipeline opportunities from a single technological foundation, a proposition that increasingly resonates with investors seeking de-risked, multi-asset exposure.
Corporate Venture Capital (CVC) in Pharmatech
Sessions on corporate venture capital in pharmatech offered insights into how CVC arms of major pharmaceutical companies evaluate AI and digital health investments. The discussions revealed that CVC appetite is shifting from broad digital health bets toward targeted investments in companies that can demonstrate measurable clinical or operational impact—particularly those integrating AI into drug discovery pipelines, real-world evidence generation, and patient engagement platforms.
The “Inside the Investor Mind” panel, featuring VCs from Forbion, Novo Holdings, Hadean Ventures, and Cancer Research Horizons, delivered one of the conference’s most consequential messages: the value inflection point for biotech investment has moved decisively beyond Phase 1.
The New Investment Calculus
The “Assessing Biotech Investment Trends in 2026 & Beyond” keynote and the “Investment, Innovation, and Influence: Reimagining Europe’s Role in Global Life Sciences” panel further reinforced a recalibration across European biotech valuations, with implications for how companies approach fundraising sequencing, milestone planning, and exit strategies in a market that rewards capital efficiency and clinical de-risking above all else.
Funding Strategies for Pre-Market Companies
Medtech and digital health companies received targeted attention through sessions on funding strategies for pre-market companies in a challenging environment. The takeaway was clear: investors are demanding clearer evidence of market fit, reimbursement pathway viability, and scalable distribution models before committing capital, particularly for medical devices and digital therapeutics where regulatory and payor dynamics remain fragmented.
One of the most visible and strategically significant trends at LSX26 was the strong presence of Asian life sciences companies, including biotechs, CROs, and many from South Korea, actively seeking to expand into European markets and establish cross-border partnerships. This international dimension was no longer peripheral; it was central to the partnering conversations.
Southern Europe’s Ascent
The panel on “Mapping Investment and Innovation in Southern Europe,” moderated by João Eurico Fonseca, Dean of the Medical School at the University of Lisbon, highlighted how Portugal, Spain, Italy, and France are emerging as credible biotech innovation hubs with growing talent pools, supportive public funding mechanisms, and increasing private capital flows. Lisbon’s selection as the inaugural non-London venue for LSX was itself a strategic signal about shifting center-of-gravity dynamics within European life sciences.
The Translational Bottleneck
A recurring and sobering theme across investor panels and company presentations was the persistent gap between scientific innovation quality and translational velocity. Multiple early-stage biotechs presented compelling novel mechanisms across rare diseases, oncology, and neurology, yet first-in-human trial timelines stretched to 2027 or 2028. The industry continues to face a translational bottleneck due to operational, regulatory, and capital-related challenges rather than scientific ones. Companies that deploy AI-powered clinical trial infrastructure, such as imaging biomarkers, adaptive trial designs, and automated data capture, to compress these timelines will hold a decisive competitive advantage.
LSX26’s three-track structure—biotech leaders, medtech leaders, and pharmatech leaders—reflected a broader industry trend: the boundaries between biological therapeutics, medical devices, and digitally-enabled pharmaceutical innovation are dissolving. For investors, this convergence creates new opportunity sets at the intersections of AI, biological innovation, and device technology. For startups, it demands strategic clarity about where they sit in a value chain that is increasingly integrated.
Medtech: Wearables, Remote Monitoring, and Women’s Health
The medtech leaders track focused on practical growth strategies, including global expansion, reimbursement pathway optimization, and emerging growth areas such as women’s health, wearable diagnostics, and remote patient monitoring. Discussions emphasized that medtech innovators must demonstrate not only clinical utility but also cost-effectiveness and integration into existing care delivery workflows to attract both venture capital and strategic acquirers.
Pharmatech: The Digital-Pharma Interface
The pharmatech track explored how pharmaceutical companies are leveraging digital tools and AI to improve clinical trial design, enhance patient adherence, and accelerate drug development timelines. Sessions also examined differences in digital health adoption between European and American markets, providing a comparative lens for companies navigating regulatory and commercial landscapes across both regions.
LSX26 was not a traditional innovation showcase; it was a strategic recalibration of the European life sciences ecosystem around several converging realities:
For healthcare and life sciences senior leaders, LSX26 highlighted a critical action: organizations that do not integrate AI into their development and commercialization strategies, secure capital for Phase 2-ready programs, and establish themselves within global partnership networks within the next 12–18 months face a fundamental disadvantage—not just a temporary lag—as these capabilities quickly become essential for the industry’s future.
By Eratha Poongkuntran, Associate Director, Avasant
Avasant’s research and other publications are based on information from the best available sources and Avasant’s independent assessment and analysis at the time of publication. Avasant takes no responsibility and assumes no liability for any error/omission or the accuracy of information contained in its research publications. Avasant does not endorse any provider, product or service described in its RadarView™ publications or any other research publications that it makes available to its users, and does not advise users to select only those providers recognized in these publications. Avasant disclaims all warranties, expressed or implied, including any warranties of merchantability or fitness for a particular purpose. None of the graphics, descriptions, research, excerpts, samples or any other content provided in the report(s) or any of its research publications may be reprinted, reproduced, redistributed or used for any external commercial purpose without prior permission from Avasant, LLC. All rights are reserved by Avasant, LLC.
Login to get free content each month and build your personal library at Avasant.com
